Literature DB >> 33434591

CKD Progression and Mortality Among Men and Women: A Nationwide Study in Sweden.

Oskar Swartling1, Helena Rydell2, Maria Stendahl3, Mårten Segelmark4, Ylva Trolle Lagerros5, Marie Evans2.   

Abstract

RATIONALE &
OBJECTIVE: Chronic kidney disease (CKD) is a global health problem with increasing prevalence. Several sex-specific differences have been reported for disease progression and mortality. Selection and survival bias might have influenced the results of previous cohort studies. The objective of this study was to investigate sex-specific differences of CKD progression and mortality among patients with CKD not receiving maintenance dialysis. STUDY
DESIGN: Observational cohort study. SETTING & PARTICIPANTS: Adult patients with incident CKD glomerular filtration rate categories 3b to 5 (G3b-G5) identified between 2010 and 2018 within the nationwide Swedish Renal Registry-CKD (SRR-CKD). EXPOSURE: Sex. OUTCOMES: Time to CKD progression (defined as a change of at least 1 CKD stage or initiation of kidney replacement therapy [KRT]) or death. Repeated assessments of estimated glomerular filtration rate (eGFR). ANALYTICAL APPROACH: CKD progression and mortality before KRT were assessed by the cumulative incidence function methods and Fine and Gray models, with death handled as a competing event. Sex differences in eGFR slope were estimated using mixed effects linear regression models.
RESULTS: 7,388 patients with incident CKD G3b, 18,282 with incident CKD G4, and 9,410 with incident CKD G5 were identified. Overall, 19.6 (95% CI, 19.2-20.0) patients per 100 patient-years progressed, and 10.1 (95% CI, 9.9-10.3) patients per 100 person-years died. Women had a lower risk of CKD progression (subhazard ratio [SHR], 0.88 [95% CI, 0.85-0.92]), and a lower all-cause (SHR, 0.90 [95% CI, 0.85-0.94]) and cardiovascular (SHR, 0.83 [95% CI, 0.76-0.90]) mortality risk. Risk factors related to a steeper decline in eGFR included age, sex, albuminuria, and type of primary kidney disease. LIMITATIONS: Incomplete data for outpatient visits and laboratory measurements and regional differences in reporting.
CONCLUSIONS: Compared to women, men had a higher rate of all-cause and cardiovascular mortality, an increased risk of CKD progression, and a steeper decline in eGFR.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CKD progression; chronic kidney disease (CKD); end-stage kidney disease (ESKD); epidemiology; estimated glomerular filtration rate (eGFR); kidney replacement therapy (KRT); mortality; primary kidney disease; sex; sex differences; sex disparities

Year:  2021        PMID: 33434591     DOI: 10.1053/j.ajkd.2020.11.026

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  19 in total

1.  Icariin attenuates renal interstitial fibrosis through G protein-coupled estrogen receptor in a UUO murine model.

Authors:  Lin Xie; Lili Fu; Changlin Mei; Yi Wang; Min Chen; Xiangchen Gu
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

2.  Sex Differences in the Recognition, Monitoring, and Management of CKD in Health Care: An Observational Cohort Study.

Authors:  Oskar Swartling; Yuanhang Yang; Catherine M Clase; Edouard L Fu; Manfred Hecking; Sebastian Hödlmoser; Ylva Trolle-Lagerros; Marie Evans; Juan J Carrero
Journal:  J Am Soc Nephrol       Date:  2022-07-29       Impact factor: 14.978

3.  Urine podocyte mRNA loss in preterm infants and related perinatal risk factors.

Authors:  Qi Gao; Congchao Lu; Xiuying Tian; Jun Zheng; Fangrui Ding
Journal:  Pediatr Nephrol       Date:  2022-06-27       Impact factor: 3.714

4.  Incidence of end-stage renal disease and risk factors for progression of renal dysfunction in Japanese patients with type 2 diabetes: the Fukuoka Diabetes Registry.

Authors:  Masanori Iwase; Hitoshi Ide; Toshiaki Ohkuma; Hiroki Fujii; Yuji Komorita; Masahito Yoshinari; Yutaro Oku; Taiki Higashi; Udai Nakamura; Takanari Kitazono
Journal:  Clin Exp Nephrol       Date:  2021-09-28       Impact factor: 2.801

5.  Frailty among chronic kidney disease patients on the kidney transplant waiting list: the sex-frailty paradox.

Authors:  María José Pérez-Sáez; Carlos E Arias-Cabrales; Vanesa Dávalos-Yerovi; Dolores Redondo; Anna Faura; María Vera; Anna Bach; Guillermo Pedreira; Ernestina Junyent; Marta Crespo; Ester Marco; Leocadio Rodríguez-Mañas; Julio Pascual
Journal:  Clin Kidney J       Date:  2021-07-10

Review 6.  Impact of Obesity in Kidney Diseases.

Authors:  Vasilios Kotsis; Fernando Martinez; Christina Trakatelli; Josep Redon
Journal:  Nutrients       Date:  2021-12-15       Impact factor: 5.717

7.  Development and validation of a novel nomogram to predict overall survival of patients with moderate to severe chronic kidney disease.

Authors:  Ning Li; Guowei Zhou; Yawei Zheng; Enchao Zhou; Weiming He; Wei Sun; Lu Zhang
Journal:  Ren Fail       Date:  2022-01-23       Impact factor: 2.606

8.  Sex-Specific Differences in Mortality and Incident Dialysis in the Chronic Kidney Disease Outcomes and Practice Patterns Study.

Authors:  Manfred Hecking; Charlotte Tu; Jarcy Zee; Brian Bieber; Sebastian Hödlmoser; Helmut Reichel; Ricardo Sesso; Friedrich K Port; Bruce M Robinson; Juan Jesus Carrero; Allison Tong; Christian Combe; Bénédicte Stengel; Roberto Pecoits-Filho
Journal:  Kidney Int Rep       Date:  2021-12-01

9.  Kidney Function, Kidney Replacement Therapy, and Mortality in Men and Women.

Authors:  Sebastian Hödlmoser; Juan Jesus Carrero; Amelie Kurnikowski; Edouard L Fu; Oskar Swartling; Wolfgang C Winkelmayer; Eva S Schernhammer; Manfred Hecking
Journal:  Kidney Int Rep       Date:  2021-12-27

10.  Blood-brain barrier and gut barrier dysfunction in chronic kidney disease with a focus on circulating biomarkers and tight junction proteins.

Authors:  Leah Hernandez; Liam J Ward; Samsul Arefin; Thomas Ebert; Agne Laucyte-Cibulskiene; Olof Heimbürger; Peter Barany; Lars Wennberg; Peter Stenvinkel; Karolina Kublickiene
Journal:  Sci Rep       Date:  2022-03-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.